Addus HomeCare Earnings Call Transcripts
Fiscal Year 2026
-
Key growth drivers included hospice revitalization and targeted census expansion, with sequential census growth expected in 2026. Rate increases in major states and technology-driven hiring and fill rate improvements support operational strength. M&A focus remains on small personal care deals and select clinical opportunities.
-
Exited Q4 in strong shape, with hiring and operational improvements setting up for robust 2026 growth. Technology initiatives like the caregiver app and AI are enhancing efficiency, while regulatory and Medicaid changes are being managed through strong compliance and state relationships. M&A focus remains on Personal Care, with integration of recent acquisitions progressing smoothly.
-
Margins have expanded to 12-13% through scale, M&A, and operational improvements, with recent acquisitions performing well. Rate increases in key states and technology adoption are supporting growth, while census is expected to rebound mid-2024. M&A and margin expansion remain top priorities.
Fiscal Year 2025
-
Fourth quarter and full-year 2025 saw strong revenue and EBITDA growth, driven by organic expansion, acquisitions, and favorable rate increases in key states. Personal Care and Hospice segments outperformed, while Home Health faced headwinds but showed signs of improvement.
-
Caregiver app adoption and operational focus are driving census and utilization growth, especially in key states. Stable margins, strategic M&A, and value-based care contracts support expansion, while technology and efficiency initiatives position the business for continued growth in 2026.
-
Strong growth in 2023 was supported by favorable Medicaid rate increases and robust hiring, with technology adoption driving operational gains. M&A remains a key strategy, focusing on personal care and smaller home health deals, while hospice and home health segments face industry normalization and reimbursement uncertainty.
-
Third quarter 2025 saw 25% revenue growth and 31.6% higher Adjusted EBITDA, driven by strong Personal Care and Hospice performance, recent acquisitions, and favorable state rate increases. Gross margin and cash flow improved, with continued momentum expected into Q4 and 2026.
-
Operating in 22 states, the company targets 10% annual growth through acquisitions and organic expansion, with a focus on personal care, hospice, and home health. Technology adoption, strong state relationships, and value-based care contracts drive efficiency and differentiation.
-
Second quarter 2025 saw 21.8% revenue growth and 24.5% higher adjusted EBITDA, driven by strong personal care and hospice performance, strategic acquisitions, and favorable state reimbursement trends. Margin expansion and further growth are expected, despite regulatory and labor headwinds.
-
Strong organic growth in personal care was driven by rate increases and improved hiring, with turnover reduced through technology. The Geneva acquisition expanded presence in Texas, and further M&A is planned. EBITDA margin is expected above 12% for 2025, supported by operational efficiencies.
-
Regulatory changes present limited risk, with Medicaid and immigration policies having minimal operational impact. Geneva integration is on track, supporting expansion in Texas and value-based care initiatives. Personal care and hospice segments show strong growth, while technology and hiring improvements drive operational efficiency.
-
Q1 2025 saw 20.3% revenue growth and 25.1% higher adjusted EBITDA, driven by strong personal care and hospice segments, successful hiring, and the Gentiva acquisition. Guidance remains positive with stable margins, ongoing acquisition focus, and minimal risk from Medicaid changes.
-
Expanded service lines and geographic density drive growth, with strong 2024 results and a positive 2025 outlook. Labor and rate environments remain favorable, supported by state partnerships and recent acquisitions, especially in Texas. Policy changes are expected to have minimal impact.
-
Redetermination disruptions have eased, with strong hiring and growth in personal care and hospice. Regulatory risks from Medicaid cuts appear limited, and states are supportive with rate increases. M&A focus is on personal care and home health, while AI-driven scheduling and caregiver apps are being piloted to boost efficiency.
-
Medicaid policy changes pose minimal risk, with work requirements potentially aiding recruitment and most clients exempt. Financial outlook is strong, supported by rate increases and strategic M&A, while Gentiva integration is progressing well. Texas remains a key growth focus.
Fiscal Year 2024
-
Q4 2024 saw 7.5% revenue and 10.3% adjusted EBITDA growth, with full-year revenue up 9.1% and EPS up 14.9%. The Gentiva acquisition expanded market reach, and 2025 guidance targets high-end organic growth, with Medicaid policy risks seen as manageable.
-
Management expects resilience regardless of election outcome, with potential regulatory tailwinds if the Medicaid Access Rule is repealed. Growth will be driven by personal care expansion, strategic M&A, and technology integration, with long-term EBITDA margins targeted at 11-12%.
-
Third quarter revenue grew 7% year-over-year to $289.8 million, with adjusted EPS up 13% and strong performance in personal care and hospice segments. The Gentiva acquisition is set to close in Q4, expanding market reach and supporting future growth.
-
Second quarter revenue grew 10.4% year-over-year to $286.9 million, with adjusted EPS up 26.2% and adjusted EBITDA up 24.7%. The company completed a $176 million equity raise, repaid all debt, and is set to close the Gentiva acquisition in Q4, supporting continued growth and margin expansion.
-
Stabilization in personal care and strong hiring have positioned the business for growth, with strategic exit from New York and a focus on expanding in key states. Value-based care initiatives and M&A remain central, supported by strong cash flow and favorable regulatory developments.